Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction
RATIONALE: Implant-based reconstruction have become the most popular choices of reconstruction for women undergoing breast mastectomy. Postoperative complications like infection and tumor recurrence limit its application. Interferons (IFNs) are pleiotropic cytokines that involve in immunoregulatory, anticancer and restricting infection. Especially, type I IFN signaling is reported favourable for the success of conventional chemotherapeutics, radiotherapy and immunotherapy. In addition, type I IFN can regulate the activity of almost all immune cell types (including T cells, macrophages and innate lymphocytes), creating a well-established immune environment to defense infectious and relapsing disease. Implants are rapidly coated with extracellular matrix proteins and immune protein components for the formation of a typical capsule. At the specific time point before implantation, the locally utilized of IFN in intracavity breast is assumed to modify cellular immune responses thus contributing to decreasing infection and tumor recurrence.
PURPOSE: This non-randomized phase I trial aims to explore dose range of IFNα-2a. Adverse events are observed to assess drug safety and human tolerance index.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510120
- Shicheng Su
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Signed the informed consent.
- Female aged between 18 and 70 years.
- Pathologically diagnosed operable breast cancer.
- WHO Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Newly diagnosed breast cancer.
The important organ functions meet the following criteria:
- WBC >=3.0 x 10^9/L; Neutrophilic granulocytes >=1.5×10^9/L; Platelet >=100 x 10^9/L; Hb >=9 g/dL;
- Total bilirubin no more than 1.5 times the normal upper limit (ULN); AST and ALT no more than 1.5 times ULN; AKP no more than 2.5 times ULN;
- Serum creatinine no more than 1.5 times ULN or Clearance rate of creatinine >= 60ml/min;
- Thyroid stimulating hormone (TSH) <= ULN (T3, T4 levels need to be detected simultaneously if abnormalities, the patient can be included if T3, T4 levels is normal);
- LVEF basement >= 50%.
Exclusion Criteria:
- Evidence of distant metastasis.
Any contraindication of nipple-areolar complex (NAC) saving mastectomy (NSM):
- Intraoperative biopsy revealed carcinoma invasion of NAC.
- Paget's disease of breast.
- Tumor distant from NAC less than 1 cm.
- Any invasive malignancy diagnosed within previous 5 years (other than successfully treated cervical carcinoma in situ, skin basal cell carcinoma or cutaneous squamous cell carcinoma).
- At least 4 months since prior interferon therapy.
- At least 3 weeks since prior major surgery requiring general anesthesia.
- At least 3 weeks since prior radiotherapy or chemotherapy.
- Hypersensitivity to interferon or other components: urticaria, angioedema, bronchial stenosis, anaphylaxis, or Stevens-Johnson syndrome.
- Prior organ allograft.
- Use of an unlicensed or other investigational drug within 4 weeks.
Any severe comorbidities, inability to give informed consent or unavailability for follow-up, including but not limited to any of the following:
- Heart failure above NYHA class 2 level; high-risk uncontrollable arrhythmia; unstable angina pectoris; myocardial infarction within 1 intervention.
- Chronic obstructive pulmonary disease requires treatment.
- Chronic liver disease (cirrhosis, chronic active hepatitis, etc.).
- Cerebrovascular accident occurred within 6 months.
- Severe epilepsy or central nervous system diseases.
- Hypertension which cannot be well controlled by antihypertensive drugs.
- Abnormal coagulation, bleeding tendency, or receiving thrombolysis or anticoagulant therapy.
- Chronic renal insufficiency.
- Active infection.
- Psychiatric disability, etc.
- Pregnant or lactating women.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Experimental: Participants with breast cancer enrolled in grou
|
After mastectomy, it is used in the cavity of breast before conducting implantation.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Dose-limiting toxicity (DLT)
大体时间:7 days after surgery
|
Dose-limiting toxicity (DLT), defined as certain grade II toxicity such as nephrotoxicity and cardiotoxicity, grade III non-hematologic toxicity and grade IV hematologic toxicity.
|
7 days after surgery
|
|
Maximal tolerable dose (MTD)
大体时间:7 days after surgery
|
Maximal tolerable dose (MTD), defined as a dose level where 2 or more subjects among 6 subjects suffering DLT.
If the experiment reached the set maximum dose without any DLT occurring, the maximum dose was defined as MTD.
|
7 days after surgery
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Adverse events (AE)
大体时间:7 days after surgery
|
7 days after surgery
|
|
Server adverse events (SAE)
大体时间:7 days after surgery
|
7 days after surgery
|
合作者和调查者
调查人员
- 首席研究员:Shicheng Su, M.D.,Ph.D.、Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.